Piotr Dobrowolski
Research Subjects
Piotr Dobrowolski has a total of 302 co-authors. Here are the top co-authors by number of shared publications:
Andrzej Januszewicz
Natl Inst Cardiol, Dept Hypertens, Warsaw, Poland
19 shared publications- Aleksander Prejbisz
Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, National Institute of Cardiology, Warsaw, Poland
18 shared publications Piotr Hoffman
Adult Congenital Heart Disease Department, Institute of Cardiology, Warsaw, Poland
15 shared publicationsAleksander Prejbisz
Natl Inst Cardiol, Dept Hypertens, Warsaw, Poland
10 shared publicationsAnna Klisiewicz
Department of Congenital Heart Diseases, Institute of Cardiology, Warsaw, Poland
10 shared publicationsMagdalena Januszewicz
Med Univ Warsaw, Dept Radiol 2, Warsaw, Poland
9 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (11)
Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics
- 2 October 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (11)
Open AccessDiet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics
- 26 February 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (10) , e1942-e1943
First, Don't Be Indifferent, Act Faster if Primary Aldosteronism Is Possible
Aleksander Prejbisz, Piotr Dobrowolski; First, don't be indifferent, act faster if primary aldosteronism is possible, The Journal of Clinical Endocrinology & Me
- 26 February 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (10) , e1942-e1943
First, Don't Be Indifferent, Act Faster if Primary Aldosteronism Is Possible
Aleksander Prejbisz, Piotr Dobrowolski; First, don't be indifferent, act faster if primary aldosteronism is possible, The Journal of Clinical Endocrinology & Me
- Top Cited Papers
- 31 January 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (1) , 8-27
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
Lipoprotein(a) [Lp(a)] is made up of a low-density lipoprotein (LDL) particle and a specific apolipoprotein(a). The blood concentration of Lp(a) is approximately 90% genetically determined, and the main genetic factor determining Lp(a) levels is the size of the apo(a) isoform, which is determined by the number of KIV2 domain repeats. The size of the apo(a) isoform is inversely proportional to the blood concentration of Lp(a). Lp(a) is a strong and independent cardiovascular risk factor. Elevated Lp(a) levels ≥ 50 mg/dl (≥ 125 nmol/l) are estimated to occur in more than 1.5 billion people worldwide. However, determination of Lp(a) levels is performed far too rarely, including Poland, where, in fact, it is only since the 2021 guidelines of the Polish Lipid Association (PoLA) and five other scientific societies that Lp(a) measurements have begun to be performed. Determination of Lp(a) concentrations is not easy due to, among other things, the different sizes of the apo(a) isoforms; however, the currently available certified tests make it possible to distinguish between people with low and high cardiovascular risk with a high degree of precision. In 2022, the first guidelines for the management of patients with elevated lipoprotein(a) levels were published by the European Atherosclerosis Society (EAS) and the American Heart Association (AHA). The first Polish guidelines are the result of the work of experts from the two scientific societies and their aim is to provide clear, practical recommendations for the determination and management of elevated Lp(a) levels.
- 31 January 2024
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 20 (1) , 8-27
Top Cited PapersRecommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels
Lipoprotein(a) [Lp(a)] is made up of a low-density lipoprotein (LDL) particle and a specific apolipoprotein(a). The blood concentration of Lp(a) is approximately 90% genetically determined, and the main genetic factor determining Lp(a) levels is the size of the apo(a) isoform, which is determined by the number of KIV2 domain repeats. The size of the apo(a) isoform is inversely proportional to the blood concentration of Lp(a). Lp(a) is a strong and independent cardiovascular risk factor. Elevated Lp(a) levels ≥ 50 mg/dl (≥ 125 nmol/l) are estimated to occur in more than 1.5 billion people worldwide. However, determination of Lp(a) levels is performed far too rarely, including Poland, where, in fact, it is only since the 2021 guidelines of the Polish Lipid Association (PoLA) and five other scientific societies that Lp(a) measurements have begun to be performed. Determination of Lp(a) concentrations is not easy due to, among other things, the different sizes of the apo(a) isoforms; however, the currently available certified tests make it possible to distinguish between people with low and high cardiovascular risk with a high degree of precision. In 2022, the first guidelines for the management of patients with elevated lipoprotein(a) levels were published by the European Atherosclerosis Society (EAS) and the American Heart Association (AHA). The first Polish guidelines are the result of the work of experts from the two scientific societies and their aim is to provide clear, practical recommendations for the determination and management of elevated Lp(a) levels.
- Open Access
- 1 August 2023
- Published by VM Media Group sp. z o.o in Choroby Serca i Naczyń
- Vol. 20 (1) , 33-39
Miejsce lisinoprilu w nowoczesnej kardiologii
Choroby układu krążenia dzielą wspólne czynniki ryzyka oraz sposoby farmakoterapii. Celem kardiologii jest ich skuteczne leczenie za pomocą leków o potwierdzonych skuteczności i bezpieczeństwie stosowania w celu ograniczania ryzyka chorobowości i śmiertelności. Jednym z przedstawicieli grupy inhibitorów konwertazy angiotensyny I, w odniesieniu do którego istnieją dowody skuteczności w szerokim wachlarzu wskazań, jest lisinopril. Badania z wykorzystaniem lisinoprilu dotyczyły szerokiej populacji pacjentów: z nadciśnieniem tętniczym, obarczonych wysokim ryzykiem sercowo-naczyniowym, otyłych, starszych, chorych w ostrej fazie zawału serca, z przewlekłą niewydolnością serca, z cukrzycą, cukrzycową chorobą nerek oraz retinopatią cukrzycową. We wszystkich badaniach lisinopril wykazywał się skutecznością nie tylko w obniżaniu ciśnienia tętniczego, lecz także zmniejszał częstość występowania powikłań narządowych i charakteryzował się bardzo dobrym profilem bezpieczeństwa. Choroby układu krążenia dzielą wspólne czynniki ryzyka oraz sposoby farmakoterapii. Celem kardiologii jest ich skuteczne leczenie za pomocą leków o potwierdzonych skuteczności i bezpieczeństwie stosowania w celu ograniczania ryzyka chorobowości i śmiertelności. Jednym z przedstawicieli grupy inhibitorów konwertazy angiotensyny I, w odniesieniu do którego istnieją dowody skuteczności w szerokim wachlarzu wskazań, jest lisinopril. Badania z wykorzystaniem lisinoprilu dotyczyły szerokiej populacji pacjentów: z nadciśnieniem tętniczym, obarczonych wysokim ryzykiem sercowo-naczyniowym, otyłych, starszych, chorych w ostrej fazie zawału serca, z przewlekłą niewydolnością serca, z cukrzycą, cukrzycową chorobą nerek oraz retinopatią cukrzycową. We wszystkich badaniach lisinopril wykazywał się skutecznością nie tylko w obniżaniu ciśnienia tętniczego, lecz także zmniejszał częstość występowania powikłań narządowych i charakteryzował się bardzo dobrym profilem bezpieczeństwa.
- 1 August 2023
- Published by VM Media Group sp. z o.o in Choroby Serca i Naczyń
- Vol. 20 (1) , 33-39
Open AccessMiejsce lisinoprilu w nowoczesnej kardiologii
Choroby układu krążenia dzielą wspólne czynniki ryzyka oraz sposoby farmakoterapii. Celem kardiologii jest ich skuteczne leczenie za pomocą leków o potwierdzonych skuteczności i bezpieczeństwie stosowania w celu ograniczania ryzyka chorobowości i śmiertelności. Jednym z przedstawicieli grupy inhibitorów konwertazy angiotensyny I, w odniesieniu do którego istnieją dowody skuteczności w szerokim wachlarzu wskazań, jest lisinopril. Badania z wykorzystaniem lisinoprilu dotyczyły szerokiej populacji pacjentów: z nadciśnieniem tętniczym, obarczonych wysokim ryzykiem sercowo-naczyniowym, otyłych, starszych, chorych w ostrej fazie zawału serca, z przewlekłą niewydolnością serca, z cukrzycą, cukrzycową chorobą nerek oraz retinopatią cukrzycową. We wszystkich badaniach lisinopril wykazywał się skutecznością nie tylko w obniżaniu ciśnienia tętniczego, lecz także zmniejszał częstość występowania powikłań narządowych i charakteryzował się bardzo dobrym profilem bezpieczeństwa. Choroby układu krążenia dzielą wspólne czynniki ryzyka oraz sposoby farmakoterapii. Celem kardiologii jest ich skuteczne leczenie za pomocą leków o potwierdzonych skuteczności i bezpieczeństwie stosowania w celu ograniczania ryzyka chorobowości i śmiertelności. Jednym z przedstawicieli grupy inhibitorów konwertazy angiotensyny I, w odniesieniu do którego istnieją dowody skuteczności w szerokim wachlarzu wskazań, jest lisinopril. Badania z wykorzystaniem lisinoprilu dotyczyły szerokiej populacji pacjentów: z nadciśnieniem tętniczym, obarczonych wysokim ryzykiem sercowo-naczyniowym, otyłych, starszych, chorych w ostrej fazie zawału serca, z przewlekłą niewydolnością serca, z cukrzycą, cukrzycową chorobą nerek oraz retinopatią cukrzycową. We wszystkich badaniach lisinopril wykazywał się skutecznością nie tylko w obniżaniu ciśnienia tętniczego, lecz także zmniejszał częstość występowania powikłań narządowych i charakteryzował się bardzo dobrym profilem bezpieczeństwa.
- Open Access
- 19 December 2022
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 132 (12)
Atherosclerotic renovascular disease and cardiovascular risk: new concepts
DOI: 10.20452/pamw.16384, Published online: December 19, 2022, Authors: Andrzej Januszewicz1*, Magdalena Januszewicz2*, Aleksander Prejbisz1, Piotr Dobrowolski1, Alexandre Persu3, Reinhold Kreutz4,5
- 19 December 2022
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 132 (12)
Open AccessAtherosclerotic renovascular disease and cardiovascular risk: new concepts
DOI: 10.20452/pamw.16384, Published online: December 19, 2022, Authors: Andrzej Januszewicz1*, Magdalena Januszewicz2*, Aleksander Prejbisz1, Piotr Dobrowolski1, Alexandre Persu3, Reinhold Kreutz4,5
- 9 September 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (11) , 2601-2610
Impact of Arterial Hypertension and Use of Antihypertensive Pharmacotherapy on Mortality in Patients Hospitalized due to COVID-19: The CRACoV-HHS Study
Background: Cardiovascular diseases including arterial hypertension are common comorbidities among patients hospitalized due to COVID-19. We assessed the influence of preexisting hypertension and its pharmacological treatment on in-hospital mortality in patients hospitalized with COVID-19. Methods: We studied all consecutive patients who were admitted to the University Hospital in Krakow, Poland, due to COVID-19 between March 2020 and May 2021. Data of 5191 patients (mean age 61.9±16.7 years, 45.2% female) were analyzed. Results: The median hospitalization time was 14 days, and the mortality rate was 18.4%. About a quarter of patients had an established cardiovascular disease including coronary artery disease (16.6%) or stroke (7.6%). Patients with hypertension (58.3%) were older and had more comorbidities than patients without hypertension. In multivariable logistic regression analysis, age above median (64 years), male gender, history of heart failure or chronic kidney disease, and higher C-reactive protein level, but not preexisting hypertension, were independent risk factors for in-hospital death in the whole study group. Patients with hypertension already treated (n=1723) with any first-line antihypertensive drug (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, or thiazide/thiazide-like diuretics) had a significantly lower risk of in-hospital death (odds ratio, 0.25 [95% CI, 0.2–0.3]; P<0.001) compared to nontreated hypertensives (n=1305). Conclusions: Although the diagnosis of preexisting hypertension per se had no significant impact on in-hospital mortality among patients with COVID-19, treatment with any first-line blood pressure–lowering drug had a profound beneficial effect on survival in patients with hypertension. These data support the need for antihypertensive pharmacological treatment during the COVID-19 pandemic. Download figure Download PowerPoint
- 9 September 2022
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (11) , 2601-2610
Impact of Arterial Hypertension and Use of Antihypertensive Pharmacotherapy on Mortality in Patients Hospitalized due to COVID-19: The CRACoV-HHS Study
Background: Cardiovascular diseases including arterial hypertension are common comorbidities among patients hospitalized due to COVID-19. We assessed the influence of preexisting hypertension and its pharmacological treatment on in-hospital mortality in patients hospitalized with COVID-19. Methods: We studied all consecutive patients who were admitted to the University Hospital in Krakow, Poland, due to COVID-19 between March 2020 and May 2021. Data of 5191 patients (mean age 61.9±16.7 years, 45.2% female) were analyzed. Results: The median hospitalization time was 14 days, and the mortality rate was 18.4%. About a quarter of patients had an established cardiovascular disease including coronary artery disease (16.6%) or stroke (7.6%). Patients with hypertension (58.3%) were older and had more comorbidities than patients without hypertension. In multivariable logistic regression analysis, age above median (64 years), male gender, history of heart failure or chronic kidney disease, and higher C-reactive protein level, but not preexisting hypertension, were independent risk factors for in-hospital death in the whole study group. Patients with hypertension already treated (n=1723) with any first-line antihypertensive drug (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, or thiazide/thiazide-like diuretics) had a significantly lower risk of in-hospital death (odds ratio, 0.25 [95% CI, 0.2–0.3]; P<0.001) compared to nontreated hypertensives (n=1305). Conclusions: Although the diagnosis of preexisting hypertension per se had no significant impact on in-hospital mortality among patients with COVID-19, treatment with any first-line blood pressure–lowering drug had a profound beneficial effect on survival in patients with hypertension. These data support the need for antihypertensive pharmacological treatment during the COVID-19 pandemic. Download figure Download PowerPoint
- 29 June 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (9) , e3689-e3698
Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma
Context: Sampling of blood in the supine position for diagnosis of pheochromocytoma and paraganglioma (PPGL) results in lower rates of false positives for plasma normetanephrine than seated sampling. It is unclear how inpatient vs outpatient testing and other preanalytical factors impact false positives.Objective: We aimed to identify preanalytical precautions to minimize false-positive results for plasma metanephrines.Methods: Impacts of different blood sampling conditions on plasma metanephrines were evaluated, including outpatient vs inpatient testing, sampling of blood in semi- vs fully recumbent positions, use of cannulae vs direct venipuncture, and differences in outside temperature. A total of 3147 patients at 10 tertiary referral centers were tested for PPGL, including 278 with and 2869 without tumors. Rates of false-positive results were analyzed.Results: Outpatient rather than inpatient sampling resulted in 44% higher plasma concentrations and a 3.4-fold increase in false-positive results for normetanephrine. Low temperature, a semi-recumbent position, and direct venipuncture also resulted in significantly higher plasma concentrations and rates of false-positive results for plasma normetanephrine than alternative sampling conditions, although with less impact than outpatient sampling. Higher concentrations and rates of false-positive results for plasma normetanephrine with low compared with warm temperatures were only apparent for outpatient sampling. Preanalytical factors were without impact on plasma metanephrines in patients with PPGL.Conclusion: Although inpatient blood sampling is largely impractical for screening patients with suspected PPGL, other preanalytical precautions (eg, cannulae, warm testing conditions) may be useful. Inpatient sampling may be reserved for follow-up of patients with difficult to distinguish true- from false-positive results.
- 29 June 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (9) , e3689-e3698
Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma
Context: Sampling of blood in the supine position for diagnosis of pheochromocytoma and paraganglioma (PPGL) results in lower rates of false positives for plasma normetanephrine than seated sampling. It is unclear how inpatient vs outpatient testing and other preanalytical factors impact false positives.Objective: We aimed to identify preanalytical precautions to minimize false-positive results for plasma metanephrines.Methods: Impacts of different blood sampling conditions on plasma metanephrines were evaluated, including outpatient vs inpatient testing, sampling of blood in semi- vs fully recumbent positions, use of cannulae vs direct venipuncture, and differences in outside temperature. A total of 3147 patients at 10 tertiary referral centers were tested for PPGL, including 278 with and 2869 without tumors. Rates of false-positive results were analyzed.Results: Outpatient rather than inpatient sampling resulted in 44% higher plasma concentrations and a 3.4-fold increase in false-positive results for normetanephrine. Low temperature, a semi-recumbent position, and direct venipuncture also resulted in significantly higher plasma concentrations and rates of false-positive results for plasma normetanephrine than alternative sampling conditions, although with less impact than outpatient sampling. Higher concentrations and rates of false-positive results for plasma normetanephrine with low compared with warm temperatures were only apparent for outpatient sampling. Preanalytical factors were without impact on plasma metanephrines in patients with PPGL.Conclusion: Although inpatient blood sampling is largely impractical for screening patients with suspected PPGL, other preanalytical precautions (eg, cannulae, warm testing conditions) may be useful. Inpatient sampling may be reserved for follow-up of patients with difficult to distinguish true- from false-positive results.
- Open Access
- 28 April 2022
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 132 (4)
Atherosclerotic cardiovascular disease burden in patients with familial hypercholesterolemia: interpretation of data on involvement of different vascular beds
DOI: 10.20452/pamw.16248, Published online: April 28, 2022, Authors: Piotr Dobrowolski1,2, Marek Kabat1, Cezary Kępka3, Andrzej Januszewicz1, Aleksander Prejbisz1
- 28 April 2022
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 132 (4)
Open AccessAtherosclerotic cardiovascular disease burden in patients with familial hypercholesterolemia: interpretation of data on involvement of different vascular beds
DOI: 10.20452/pamw.16248, Published online: April 28, 2022, Authors: Piotr Dobrowolski1,2, Marek Kabat1, Cezary Kępka3, Andrzej Januszewicz1, Aleksander Prejbisz1
- 18 October 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (2) , 325-334
Blood Pressure and Arterial Stiffness in Association With Aircraft Noise Exposure:Long-Term Observation and Potential Effect of COVID-19 Lockdown
In a cross-sectional analysis of a case-control study in 2015, we revealed the association between increased arterial stiffness (pulse wave velocity) and aircraft noise exposure. In June 2020, we evaluated the long-term effects, and the impact of a sudden decline in noise exposure during the coronavirus disease 2019 (COVID-19) lockdown, on blood pressure and pulse wave velocity, comparing 74 participants exposed to long-term day-evening-night aircraft noise level > 60 dB and 75 unexposed individuals. During the 5-year follow-up, the prevalence of hypertension increased in the exposed (42% versus 59%, P =0.048) but not in the unexposed group. The decline in noise exposure since April 2020 was accompanied with a significant decrease of noise annoyance, 24-hour systolic (121.2 versus 117.9 mm Hg; P =0.034) and diastolic (75.1 versus 72.0 mm Hg; P =0.003) blood pressure, and pulse wave velocity (10.2 versus 8.8 m/s; P =0.001) in the exposed group. Less profound decreases of these parameters were noticed in the unexposed group. Significant between group differences were observed for declines in office and night-time diastolic blood pressure and pulse wave velocity. Importantly, the difference in the reduction of pulse wave velocity between exposed and unexposed participants remained significant after adjustment for covariates (−1.49 versus −0.35 m/s; P =0.017). The observed difference in insomnia prevalence between exposed and unexposed individuals at baseline was no more significant at follow-up. Thus, long-term aircraft noise exposure may increase the prevalence of hypertension and accelerate arterial stiffening. However, even short-term noise reduction, as experienced during the COVID-19 lockdown, may reverse those unfavorable effects.
- 18 October 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 79 (2) , 325-334
Blood Pressure and Arterial Stiffness in Association With Aircraft Noise Exposure:Long-Term Observation and Potential Effect of COVID-19 Lockdown
In a cross-sectional analysis of a case-control study in 2015, we revealed the association between increased arterial stiffness (pulse wave velocity) and aircraft noise exposure. In June 2020, we evaluated the long-term effects, and the impact of a sudden decline in noise exposure during the coronavirus disease 2019 (COVID-19) lockdown, on blood pressure and pulse wave velocity, comparing 74 participants exposed to long-term day-evening-night aircraft noise level > 60 dB and 75 unexposed individuals. During the 5-year follow-up, the prevalence of hypertension increased in the exposed (42% versus 59%, P =0.048) but not in the unexposed group. The decline in noise exposure since April 2020 was accompanied with a significant decrease of noise annoyance, 24-hour systolic (121.2 versus 117.9 mm Hg; P =0.034) and diastolic (75.1 versus 72.0 mm Hg; P =0.003) blood pressure, and pulse wave velocity (10.2 versus 8.8 m/s; P =0.001) in the exposed group. Less profound decreases of these parameters were noticed in the unexposed group. Significant between group differences were observed for declines in office and night-time diastolic blood pressure and pulse wave velocity. Importantly, the difference in the reduction of pulse wave velocity between exposed and unexposed participants remained significant after adjustment for covariates (−1.49 versus −0.35 m/s; P =0.017). The observed difference in insomnia prevalence between exposed and unexposed individuals at baseline was no more significant at follow-up. Thus, long-term aircraft noise exposure may increase the prevalence of hypertension and accelerate arterial stiffening. However, even short-term noise reduction, as experienced during the COVID-19 lockdown, may reverse those unfavorable effects.
- 1 October 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 78 (4) , 898-911
Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension
Renovascular hypertension is one of the most common forms of secondary hypertension. Over 95% of cases of renovascular hypertension are due either to atherosclerosis of the main renal artery trunks or to fibromuscular dysplasia. These two causes of renal artery stenosis have been extensively discussed in recent reviews and consensus. The aim of the current article is to provide comprehensive and up-to-date information on the remaining causes. While these causes are rare or extremely rare, etiologic and differential diagnosis matters both for prognosis and management. Therefore, the clinician cannot ignore them. For didactic reasons, we have grouped these different entities into stenotic lesions (neurofibromatosis type 1 and other rare syndromes, dissection, arteritis, and segmental arterial mediolysis) often associated with aortic coarctation and other arterial abnormalities, and nonstenotic lesions, where hypertension is secondary to compression of adjacent arteries and changes in arterial pulsatility (aneurysm) or to the formation of a shunt, leading to kidney ischemia (arteriovenous fistula). Finally, thrombotic disorders of the renal artery may also be responsible for renovascular hypertension. Although thrombotic/embolic lesions do not represent primary vessel wall disease, they are characterized by frequent macrovascular involvement. In this review, we illustrate the most characteristic aspects of these different entities responsible for renovascular hypertension and discuss their prevalence, pathophysiology, clinical presentation, management, and prognosis.
- 1 October 2021
- Published by Wolters Kluwer Health in Hypertension
- Vol. 78 (4) , 898-911
Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension
Renovascular hypertension is one of the most common forms of secondary hypertension. Over 95% of cases of renovascular hypertension are due either to atherosclerosis of the main renal artery trunks or to fibromuscular dysplasia. These two causes of renal artery stenosis have been extensively discussed in recent reviews and consensus. The aim of the current article is to provide comprehensive and up-to-date information on the remaining causes. While these causes are rare or extremely rare, etiologic and differential diagnosis matters both for prognosis and management. Therefore, the clinician cannot ignore them. For didactic reasons, we have grouped these different entities into stenotic lesions (neurofibromatosis type 1 and other rare syndromes, dissection, arteritis, and segmental arterial mediolysis) often associated with aortic coarctation and other arterial abnormalities, and nonstenotic lesions, where hypertension is secondary to compression of adjacent arteries and changes in arterial pulsatility (aneurysm) or to the formation of a shunt, leading to kidney ischemia (arteriovenous fistula). Finally, thrombotic disorders of the renal artery may also be responsible for renovascular hypertension. Although thrombotic/embolic lesions do not represent primary vessel wall disease, they are characterized by frequent macrovascular involvement. In this review, we illustrate the most characteristic aspects of these different entities responsible for renovascular hypertension and discuss their prevalence, pathophysiology, clinical presentation, management, and prognosis.